14-3-3 protein cerebrospinal fluid detection in human growth hormone-treated Creutzfeldt-Jakob disease patients.
The usefulness of the detection of 14-3-3 protein in the cerebrospinal fluid (CSF) in the diagnosis of Creutzfeldt-Jakob disease transmitted from human growth hormone was evaluated in 20 French patients. The 14-3-3 protein was rarely detectable within the first 3 months of the disease but always positive after 7 months associated with the aggravation of the disease and the occurrence of dementia. 14-3-3 detection was not predictive of the survival time of the patients. The genotype at PRNP codon 129 could influence the timing of appearance of the 14-3-3 protein in the CSF.
Brandel
J P
JP
Centre National de Référence de la MCJ iatrogène, H pital de la Salpêtrière, INSERM U360, Paris, France.
Peoc'h
K
K
Beaudry
P
P
Welaratne
A
A
Bottos
C
C
Agid
Y
Y
Laplanche
J L
JL
D048948:14-3-3 Proteins; D007562:Creutzfeldt-Jakob Syndrome / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D014446:Tyrosine 3-Monooxygenase / Q000134:cerebrospinal fluid*
D048948:14-3-3 Proteins; D013006:Growth Hormone; D014446:Tyrosine 3-Monooxygenase